Literature DB >> 18955102

Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample.

B Doornbos1, S A van Goor, D A J Dijck-Brouwer, A Schaafsma, J Korf, F A J Muskiet.   

Abstract

BACKGROUND: The decrease of maternal docosahexaenoic (DHA) status during pregnancy has been associated with postpartum depression, especially in women with a low intake of DHA. Since the DHA intake in the Netherlands is low, we investigated whether supplementation of low doses of DHA or DHA plus arachidonic acid (AA) during pregnancy and lactation could prevent depressive symptoms and sleep disturbances in this period.
METHODS: Women were supplemented daily with placebo, DHA (220 mg) or DHA+AA (220 mg each) from week 16 of pregnancy till three months postpartum. Fatty acid analyses were performed in the available plasma samples at 16 and 36 weeks of pregnancy. Depressive symptoms were measured in weeks 16 and 36 of pregnancy and six weeks postpartum using EPDS and within one week postpartum using a blues questionnaire.
RESULTS: 119 women completed the study. The average frequency of fish intake was low, 0.94 times per week, and did not differ between the groups. The supplementation groups did not differ in mean EPDS scores or changes in EPDS scores, nor in incidence or severity of postpartum blues. Red blood cell DHA, AA and DHA/AA ratio did not correlate with EPDS or blues scores. Indices of sleep quality did not differ between the groups.
CONCLUSION: Supplementation of 220 mg/day DHA or DHA+AA (220 mg/day each) does not prevent peri-partum depressive symptoms, in a population based sample with low background DHA intake. TRIAL REGISTRATION: ISRCTN Register nr. ISRCTN58176213.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955102     DOI: 10.1016/j.pnpbp.2008.10.003

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  25 in total

Review 1.  Maternal omega-3 fatty acid supplementation and risk for perinatal maternal depression.

Authors:  Janet M Wojcicki; Melvin B Heyman
Journal:  J Matern Fetal Neonatal Med       Date:  2010-10-07

2.  Selective dietary supplementation in early postpartum is associated with high resilience against depressed mood.

Authors:  Yekta Dowlati; Arun V Ravindran; Zindel V Segal; Donna E Stewart; Meir Steiner; Jeffrey H Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-13       Impact factor: 11.205

3.  High dietary ratio of omega-6 to omega-3 polyunsaturated acids during pregnancy and prevalence of post-partum depression.

Authors:  Camilla M M da Rocha; Gilberto Kac
Journal:  Matern Child Nutr       Date:  2010-06-21       Impact factor: 3.092

Review 4.  Fatty acid status and maternal mental health.

Authors:  Usha Ramakrishnan
Journal:  Matern Child Nutr       Date:  2011-04       Impact factor: 3.092

Review 5.  Preventing postpartum depression: review and recommendations.

Authors:  Elizabeth Werner; Maia Miller; Lauren M Osborne; Sierra Kuzava; Catherine Monk
Journal:  Arch Womens Ment Health       Date:  2014-11-25       Impact factor: 3.633

Review 6.  Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy.

Authors:  Tim Schindler; John Kh Sinn; David A Osborn
Journal:  Cochrane Database Syst Rev       Date:  2016-10-28

Review 7.  Pharmacotherapy of postpartum depression: an update.

Authors:  Deborah R Kim; C Neill Epperson; Amy R Weiss; Katherine L Wisner
Journal:  Expert Opin Pharmacother       Date:  2014-04-29       Impact factor: 3.889

Review 8.  Complementary and alternative medicine therapies for perinatal depression.

Authors:  Kristina M Deligiannidis; Marlene P Freeman
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2013-08-26       Impact factor: 5.237

9.  N-3 (omega-3) Fatty acids in postpartum depression: implications for prevention and treatment.

Authors:  Beth Levant
Journal:  Depress Res Treat       Date:  2010-10-27

Review 10.  (N-3) Fatty acids: molecular role and clinical uses in psychiatric disorders.

Authors:  Pedro Luis Prior; José Carlos Fernandes Galduróz
Journal:  Adv Nutr       Date:  2012-05-01       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.